期刊
ALZHEIMERS & DEMENTIA
卷 18, 期 12, 页码 2518-2526出版社
WILEY
DOI: 10.1002/alz.12573
关键词
Alzheimer's disease; APOE genotype; cerebral atrophy; cognitive impairment; vascular dementia
资金
- NIH [75N92019D00027, 75N92019D00028, 75N92019D00029, 75N92019D00030, U01HL41642, U01HL41652, U01HL41654, U01HL65520, U01HL65521, R01HL109315, R01HL109301, R01HL109284, R01HL109282, R01HL109319]
- NIH
- Arizona Alzheimer's Consortium
- Lilly/Avid
- Genentech/Roche
- [R01HL093086]
- [P50AG005136]
- [K01AG057821]
This study found no evidence of an association between the APOE epsilon 4 allele and neurodegenerative risk in American Indians. Further research is needed to explore potential protective features.
Background The apolipoprotein E (APOE) epsilon 4 allele confers higher risk of neurodegeneration and Alzheimer's disease (AD), but differs by race/ethnicity. We examined this association in American Indians. Methods The Strong Heart Study is a population-based cohort of American Indians who were 64 to 95 years of age in 2010 to 2013. APOE epsilon 4 status, brain imaging, and neuropsychological testing was collected in N = 811 individuals. Summary statistics, graphics, and generalized linear regressions-adjusted for sociodemographics, clinical features, and intracranial volume with bootstrap variance estimator-compared APOE epsilon 4 carriers with non-carriers. Results APOE epsilon 4 carriers comprised 22% of the population (0.7% homozygotes). Participants were mean 73 years, 67% female, and 54% had some college education. The majority were obese (>50%), hypertensive (>80%), and diabetic (>50%). Neither imaging findings nor multidomain cognitive testing showed any substantive differences between APOE epsilon 4 carriers and non-carriers. Conclusion We found no evidence of neurodegenerative risk from APOE epsilon 4 in American Indians. Additional studies are needed to examine potential protective features.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据